琥珀酸他舒格替尼最新公布价格表

Tasugatinib succinate is a targeted drug for FGFR2 fusion gene-positive unresectable biliary tract cancer that has progressed after chemotherapy. Its latest price announcement and rational medication plan have attracted much attention. This article will provide patients and their families with comprehensive medication guidance and cost analysis from three aspects: price details, medication preparation, and contraindications.

The latest announced price of tasugatinib succinate

The pricing is directly related to its clinical value. Patients need to fully understand the cost structure to plan long-term treatment.

Price and specifications

Tasugatinib succinate is an oral fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor independently developed by Eisai Tsukuba Research Laboratory. Its specification is 35mg*56 tablets per box. The price per box is approximately US$7,131. This price does not include additional expenses such as international logistics, customs duties and pharmacy service fees.

Additional charges

Cold chain transportation fees are required for cross-border purchases of tasugatinib succinate. Some countries impose drug import taxes. Partial fee reductions can be applied for through charitable aid projects. The specific fee reductions are not yet clear.

Patients are advised to obtain drugs through formal channels and keep complete drug purchase receipts for inspection.

Preparation for the administration of tasugatinib succinate

Standardizing the preparation before administration directly affects the therapeutic effect, and medical guidance must be strictly followed.

Baseline testing and evaluation

Liver function (ALT/AST), renal function (creatinine clearance) and electrocardiogram tests need to be completed before medication. Tumor gene testing (such as ALK/ROS1 mutation) is a necessary prerequisite, and positive patients can start treatment. Those with fertility needs need to complete pregnancy screening before treatment.

Hepatic Impairment

Because tasugatinib succinate is primarily metabolized in the liver, patients with impaired hepatic function may be at risk for increased blood levels when using this drug. Because clinical trials have not yet been conducted in patients with impaired liver function, the safety and effectiveness of this drug in such patients cannot be accurately assessed.

Contraindications of tasugatinib succinate

Clear contraindications are a prerequisite for safe medication, and patients must strictly follow them to avoid serious risks.

Absolute contraindications for ingredient allergy

It is contraindicated in patients with a history of allergy to the active ingredient or excipients of tasugatinib succinate (such as lactose, magnesium stearate). Anaphylaxis may manifest as rash, dyspnea, or angioedema. Symptoms require immediate discontinuation of the drug and anti-allergic treatment.

Restrictions for special groups

Pregnant and lactating women are prohibited from using it. Animal experiments show that the drug is embryotoxic. Male and female patients who plan to have children need to take effective contraceptive measures during treatment and within 3 months after stopping the drug. The safety of the drug in adolescents under 18 years of age has not been established.

Contraindications must be comprehensively evaluated by a specialist before use, and alternative treatment options must be selected to balance risks and benefits if necessary.